ARDX Ardelyx, Inc.

NASDAQ
$4.06

Ardelyx, Inc. (ARDX) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.02 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.3% since its last earnings release on August 6, 2026.

Ardelyx Missed Consensus Estimates, Lowers Guidance
Thursday, August 6, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 4:00 PM ET
Earnings Whisper
-
vs ($0.02)
Rev est $151.71M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $3.98

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Ardelyx, Inc.

Ardelyx Inc is a clinical stage biopharmaceutical company. The Company engages in the discovery, development & commercialization of non-systemic, molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal & metabolic diseases.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Held By 1 ETFs, by dollar flow